Carboxylesterase 1 (CES1) Genotype | Impact of CES1 Genotype on Metabolism of Methylphenidate
Carboxylesterase 1 (CES1) Genotype research study
What is the primary objective of this study?
The purpose of this study is to determine whether differences in the gene coding for the
liver enzyme carboxylesterase 1 (CES1) means differences in the metabolism of
methylphenidate, a CES1 dependent drug.
Who is eligible to participate?
- > 18 years old
- Chronic disease (except hay fever and eczema)
- High level of alcohol consumption (> 21 units per week for men and 14 for women)
- Known allergy towards methylphenidate
- Permanent use of medication (contraception ok)
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Carboxylesterase 1 (CES1) Genotype
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Drug:Methylphenidate10 mg as a single dose followed by one blood sample 3 hours post-dose
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
Start Date: March 2014
Phase: Phase 4
Primary Outcome: Plasma concentration of methylphenidate and ritalinic acid
Secondary Outcome: Metabolomic Profile
Study sponsors, principal investigator, and references
Principal Investigator: Claus Stage, M.D.
Lead Sponsor: Bispebjerg Hospital
Collaborator: The Ministry of Science, Technology and Innovation, Denmark